WuXi Biologics has signed a Memorandum of Understanding (MoU) with the Qatar Free Zones Authority (QFZ) to extend WuXi Biologics' global network and capabilities to the Middle East.

The Memorandum of Understanding was signed by HE Sheikh Mohammed Bin Hamad Bin Faisal Al-Thani, CEO, Qatar Free Zones Authority, and Dr Chris Chen, CEO, WuXi Biologics in the presence of HE Sheikh Faisal bin Thani bin Faisal Al-Thani, Minister of Commerce and Industry, Qatar and Chairman, Qatar Free Zones Authority.

The collaboration paves the way for the establishment of WuXi Biologics' first integrated Contract Research, Development, and Manufacturing Organization (CRDMO) centre in the Middle East.

Speaking in this regard, Dr Chris Chen, CEO, WuXi Biologics, commented, "This partnership is a pivotal step for WuXi Biologics. It marks the beginning of our journey in the region while extending our global network and capabilities. Qatar's forward-looking vision for the biopharmaceutical sector, underpinned by QFZ's integrated ecosystem and reliable connectivity, provides a compelling platform for innovation and advanced manufacturing. We look forward to contributing to this growing ecosystem while enabling our clients to deliver high-quality, life-saving treatments to patients around the world."

By combining WuXi Biologics' CRDMO solutions, technologies and expertise in complex biologics (such as bispecifics and multispecifics, antibody-drug conjugates) with Qatar's vision for biopharmaceutical advancement, this collaboration aims to drive innovation, accelerate the growth of Qatar's biotechnology sector, while jointly propel the development of a robust Middle Eastern biopharmaceutical ecosystem.

HE Sheikh Mohammed Bin Hamad Bin Faisal Al-Thani, CEO, Qatar Free Zones Authority (QFZ), said, "This partnership strengthens Qatar's position as one of the region's most reliable locations for biopharmaceutical growth. By combining WuXi Biologics' global expertise with Qatar's advanced healthcare ecosystem, supportive regulatory landscape, and exceptional logistics connectivity, we are creating an environment for sustained biopharmaceutical innovation and high-value manufacturing. We are committed to fostering strategic partnerships that expand global capacity, accelerate breakthroughs, and position Qatar as a hub for the industries of the future."